Get In Touch
Xeraya Capital Sdn Bhd
26.03–26.08, G Tower
#199 Jalan Tun Razak, KL
xeraya@xeraya.com
+603 2381 8700
Submit a Proposal
proposal@xeraya.com
Back

News & Events

Latest news and events related to our activities and our portfolio partners.
InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization
  • Xeraya Admin
  • Posted by Xeraya Admin
October 4, 2022
5 min read

InterVenn Biosciences Expands Board of Directors with Dr. Jason Myers and Carol Berry to Support Next Phase of Growth

Endpoint Health Unveils Precision Immunology Program to Address Tissue Factor-Mediated Inflammation in Autoimmune Diseases
  • Xeraya Admin
  • Posted by Xeraya Admin
October 4, 2022
5 min read

Endpoint Health Unveils Precision Immunology Program to Address Tissue Factor-Mediated Inflammation in Autoimmune Diseases

P2 Science Wins the Prestigious BeautyMatter NEXT Award for Best Breakthrough Supplier
  • Xeraya Admin
  • Posted by Xeraya Admin
September 19, 2022
3 min read

P2 Science Wins the Prestigious BeautyMatter NEXT Award for Best Breakthrough Supplier

dbn2-2022
  • Xeraya Admin
  • Posted by Xeraya Admin
September 12, 2022
1 min read

InterVenn Biosciences at the Launch of DBN 2.0

sdgesg2022
  • Xeraya Admin
  • Posted by Xeraya Admin
August 24, 2022
1 min read

Malaysia SDG and ESG Impact Awards

InterVenn Biosciences to make Malaysia its regional hub
  • Xeraya Admin
  • Posted by Xeraya Admin
August 3, 2022
3 min read

InterVenn Biosciences to make Malaysia its regional hub

InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization
  • Xeraya Admin
  • Posted by Xeraya Admin
August 2, 2022
4 min read

InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study

Congenica appoints Robert Denison as CEO
  • Xeraya Admin
  • Posted by Xeraya Admin
June 22, 2022
3 min read

Congenica appoints Robert Denison as CEO

InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization
  • Xeraya Admin
  • Posted by Xeraya Admin
June 1, 2022
4 min read

InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums to Introduce a Glycoproteomic Option for Liquid Biopsies

Congenica wins Technology Company of the Year
  • Xeraya Admin
  • Posted by Xeraya Admin
May 12, 2022
2 min read

Congenica wins Technology Company of the Year

Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
  • Xeraya Admin
  • Posted by Xeraya Admin
May 3, 2022
3 min read

Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia

P2 Science Wins the Prestigious BeautyMatter NEXT Award for Best Breakthrough Supplier
  • Xeraya Admin
  • Posted by Xeraya Admin
May 3, 2022
3 min read

Living Proof and P2 Science Announce New Partnership

Congenica Appoints Dr. Tom Barber as Chief Scientific Officer
  • Xeraya Admin
  • Posted by Xeraya Admin
May 3, 2022
3 min read

Congenica Appoints Dr. Tom Barber as Chief Scientific Officer

Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping Catheter
  • Xeraya Admin
  • Posted by Xeraya Admin
April 27, 2022
4 min read

Acutus Medical sells left-heart access portfolio to Medtronic in $50M deal

InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization
  • Xeraya Admin
  • Posted by Xeraya Admin
March 15, 2022
4 min read

AI Biotech Lands In Victoria To Advance Early Cancer Detection

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day
  • Xeraya Admin
  • Posted by Xeraya Admin
February 4, 2022
2 min read

Brief: Greenlight Biosciences completes $1.2bn merger to list on Nasdaq, closes up 5%

Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/ Enmetazobactam Met Criteria for Superiority
  • Xeraya Admin
  • Posted by Xeraya Admin
January 13, 2022
5 min read

Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra's Antibiotic Cefepime/ enmetazobactam in Europe

MVCA Awards 2020/2021
  • Xeraya Admin
  • Posted by Xeraya Admin
December 15, 2021
1 min read

MVCA Awards 2020/2021

Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
  • Xeraya Admin
  • Posted by Xeraya Admin
December 13, 2021
6 min read

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control Platform

Foghorn Therapeutics
  • Xeraya Admin
  • Posted by Xeraya Admin
November 30, 2021
5 min read

GreenLight Biosciences (ENVI) partners with IAVI to accelerate COVID-19 vaccine trial in Africa

Foghorn Therapeutics
  • Xeraya Admin
  • Posted by Xeraya Admin
November 23, 2021
3 min read

Serum Life Sciences invests in RNA biotech GreenLight by joining expanded financing for Environmental Impact Acquisition Corp.

Congenica wins Technology Company of the Year
  • Xeraya Admin
  • Posted by Xeraya Admin
September 21, 2021
4 min read

Congenica is Joint Winner of MIT Solve The Horizon Prize

Foghorn Therapeutics
  • Xeraya Admin
  • Posted by Xeraya Admin
August 10, 2021
4 min read

mRNA Disruptor Goes Public in $1.5 Billion SPAC Deal

Foghorn Therapeutics
  • Xeraya Admin
  • Posted by Xeraya Admin
August 2, 2021
3 min read

InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development